 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
PAREXEL International (PRXL) provides clinical research, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology, and medical device industries worldwide.
The company operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS), and Perceptive Informatics (Perceptive).
The CRS segment offers clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management and biostatistics, epidemiology and health economics/outcomes research, clinical logistics, pharmacovigilance, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. This segment manages various aspects of clinical trials, including study and protocol design, case report form design, paper or electronic questionnaires design, patient enrollment, study monitoring and data collection, data analysis, report writing, and medical services. The PCMS segment provides technical expertise and advice in various areas, such as drug development, regulatory affairs, product pricing and reimbursement, and good manufacturing practice compliance consulting; and market development, product development, and targeted communications services in support of product launch. Its consultants also identify alternatives and propose solutions to address clients product development, registration, and commercialization issues.
Shares have formed a bullish "cup & handle" and higher prices are expected for this stock.
52-Wee Trading Range: $23.75 - $39.61
Entry Point: $39.40
Stop Loss: $37.44
Target Price: $43.35
PRXL position closed at $40.70 after our 30-days expired without reaching 10%.
